#Non-Small Cell Lung Cancer Market

[healthcareporium]

Innovating Lung Cancer Care: Antibody-Drug Conjugates Lead the Way

The ENHERTU Effect: A Closer Look at the Dynamic Duo Daiichi Sankyo and AstraZeneca Taking on HER2-mutant NSCLC Lung cancer remains one of the most challenging and prevalent forms of cancer. Within this landscape, innovative treatments are offering new hope. One such breakthrough is the collaboration between Daiichi Sankyo and AstraZeneca, which brings forth ENHERTU, an Antibody-Drug Conjugate…

[marketwire]

The global non small cell lung cancer market size was valued at $15.3 billion in 2021, and is projected to reach $36.9 billion by 2031, growing at a CAGR of 9.3% from 2022 to 2031.

[luckydige45]

According to Nova One Advisor, the global non-small cell lung cancer therapeutics market size was estimated at USD 19.85 billion in 2023, USD 22.39 billion in 2024, and is expected to grow at a CAGR of 12.8% to reach USD 66.20 billion by 2033.

[soumyafwr]

Drugs for Non-small Cell Lung Cancer Market Analysis, Size, Share, and Forecast 2031

[futuretonext]

The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during the forecast period, i.e., 2022-27. Most of the market growth would be driven by the growing number of patients with Non-Small Cell Lung Cancer (NSCLC) type of lung cancer and the mounting demand for its effective diagnosis & treatment worldwide. 

[blogomonaco]

Immunotherapy Revolution in Non-Small Cell Lung Cancer Treatment

Immunotherapy has revolutionized the treatment of non-small cell lung cancer (NSCLC) by harnessing the power of the immune system to fight cancer cells.

Read More: https://blogconnoisseur.blogspot.com/2023/06/non-small-cell-lung-cancer-unraveling.html

[qyresearchmedica]

The global Non-Small Cell Lung Cancer (NSCLC) market size is expected to reach USD 13.51 Billion in 2030 and register a revenue CAGR of 6.8% during the forecast period.

[darkmaga-returns]

If you have not run your eyes over this, it’s worth doing it now, if you’ve time:

BioNTech—the virtual company with a virtual moral compass

You will hear: “Only ever having procured material for Phase 1 clinical trials in melanoma, using contract manufacturers, BioNTech takes on a full scale, commercial manufacturing plant!!! It also seems it had another two manufacturing plants that have appeared from nowhere.

Hopefully, you are taking in the impossibility of what has happened here.”

What is ‘virtual’ drug development?

Virtual drug development emerged following Big Pharma’s mass outsourcing of its physical assets—facilities and people skills—to third party contractors. It began in the early 1980s and has carried on afoot ever since. That was followed by Big Pharma outsourcing drug development, as well as its facilities and people skills, to reduce exposure to failed early stage clinical trials (it didn’t).

Enter virtual pharma, small companies using the third party contractor base to develop one compound, sometimes a couple, they had high hopes for.

In the early days of virtual pharma (1995 - 2005s) the virtual pharma companies had all the drug development skills in-house and managed the contractors to progress compounds through the development lifecycle. I worked for two that managed to get drugs to market, one a triptan (2002 for migraine) and the other a drug for non-small cell lung cancer (2004).

As time went by, virtual pharma became smaller and smaller, and the contractor base consolidated, to create powerful corporations, skilled at striking tough deals.

Today, if you look at the websites of the thousands of virtual pharma companies developing drugs at very early stage, the senior teams mainly comprise CEO plus finance, marketing, legal, scientific discovery, business development, alliances…with little or no expertise in the tricky business of getting drugs to market.

This is how the BioNTech team looks:

From Discovery to Delivery – Meet our Senior Team

This is the Moderna leadership Team [page not found today!]

This is the virtual pharma of today—top heavy management boards with little or no experience of developing new molecular entities for patient markets.

[industryexperts]

(via Global Lung Cancer Therapeutics Market | Trends, Forecast 2024-2030)

The lung cancer therapeutics market in 2024 is dominated by the non-small cell lung cancer (NSCLC) type, which holds an estimated 85.3% share due to its high prevalence and the development of targeted therapies and immunotherapies. These advancements specifically target genetic mutations such as EGFR, ALK, and ROS1, providing personalized treatment options and improving patient outcomes with immune checkpoint inhibitors like pembrolizumab and nivolumab. Conversely, the small cell lung cancer (SCLC) segment is anticipated to register the fastest CAGR of 11% during the forecast period 2024-2030, driven by increasing smoking rates and greater awareness of available treatments. While traditional SCLC therapies primarily consist of chemotherapy and radiotherapy, the introduction of new treatments like immune checkpoint inhibitors is beginning to improve survival rates, leading to a surge in global demand for lung cancer therapeutics.

[stevenwilliam12]

The Evolving B7-H3 Market: Size, Forecast, and Competitive Dynamics by 2034

Introduction to B7-H3 and Its Role in Oncology

B7-H3, a member of the B7 family of immune checkpoint molecules, has emerged as a promising target in cancer immunotherapy due to its significant role in immune evasion and tumor progression. Overexpressed in various cancers such as prostate cancer, non-small cell lung cancer (NSCLC), breast cancer, and pediatric tumors like neuroblastoma, B7-H3 has sparked interest for therapeutic interventions. As research into immune checkpoint inhibitors continues, the B7-H3 antibody market and B7-H3 inhibitors market size are poised for significant growth. These therapies are expected to provide new hope for patients, particularly those with cancers that exhibit resistance to conventional treatments.

B7-H3 Inhibitors Market Overview

The B7-H3 inhibitors market is emerging as a key segment within the broader immuno-oncology landscape. B7-H3-targeted therapies, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and CAR-T cell therapies, are being actively developed to treat cancers with high B7-H3 expression. The B7-H3 inhibitors market size is expected to experience substantial growth over the next decade as clinical trials progress and regulatory approvals become imminent. The market’s growth is also fueled by the increasing prevalence of cancers where B7-H3 is overexpressed, combined with a growing focus on personalized therapies that target tumor-specific biomarkers.

Target Population for B7-H3 Inhibitors

The target population for B7-H3 inhibitors consists primarily of patients diagnosed with cancers that exhibit high B7-H3 expression. Key cancer types that are likely to benefit from B7-H3 inhibitors include:

Prostate Cancer: B7-H3 is frequently overexpressed in prostate cancer, particularly in advanced stages, making it an ideal therapeutic target for mAbs and other B7-H3-targeted therapies.

Non-Small Cell Lung Cancer (NSCLC): B7-H3 has been identified as a key player in the progression of NSCLC, with high levels of expression in a significant portion of patients, making it a promising target for immunotherapy.

Breast Cancer: Certain subtypes of breast cancer, such as triple-negative breast cancer (TNBC), show elevated levels of B7-H3, and targeting this molecule may provide significant therapeutic benefits.

Pediatric Cancers: Neuroblastoma, a common pediatric cancer, is known for its overexpression of B7-H3, making it a prime target for B7-H3-directed therapies. Other pediatric cancers, such as medulloblastoma, may also benefit from these therapies.

The growing understanding of B7-H3's role in tumor progression is likely to expand the target population for these therapies, making them applicable to a broader range of cancers over time.

Competitive Landscape of the B7-H3 Inhibitors Market

The B7-H3 inhibitors market is highly competitive, with several biopharmaceutical companies actively developing innovative therapies targeting B7-H3. These therapies include monoclonal antibodies, bispecific antibodies, ADCs, and CAR-T therapies, all of which are progressing through clinical trials. Some of the key players in the B7-H3 antibody market and inhibitors landscape include:

MacroGenics: MacroGenics is at the forefront of developing enoblituzumab, a monoclonal antibody targeting B7-H3. The company is conducting clinical trials to assess the efficacy of enoblituzumab in various cancers, including prostate cancer and NSCLC.

AstraZeneca: Known for its work in antibody-drug conjugates (ADCs), AstraZeneca is advancing B7-H3-targeted ADCs to deliver potent cytotoxic drugs directly to cancer cells, offering a more precise treatment option for patients with B7-H3-positive tumors.

ImmunoGen: ImmunoGen is developing B7-H3-targeted ADCs designed to deliver toxic payloads specifically to cancer cells expressing B7-H3. Their approach aims to improve treatment outcomes while minimizing off-target effects.

Novartis: Novartis is pursuing CAR-T cell therapies that target B7-H3, particularly in pediatric cancers like neuroblastoma, which is known for its high B7-H3 expression.

Other Emerging Players: Other companies such as GSK, Bristol Myers Squibb, and AbbVie are also exploring B7-H3 inhibitors and therapies, positioning themselves as key competitors in this growing market.

As the clinical trials for these therapies progress and more results become available, the competitive landscape will continue to evolve, with collaborations and partnerships likely to play a significant role in the development of B7-H3-targeted treatments.

B7-H3 Market Forecast to 2034

The B7-H3 market is projected to experience rapid growth through 2034, driven by advances in drug development, a deeper understanding of tumor biology, and increasing investment in oncology research. The B7-H3 inhibitors market size is expected to reach multi-billion-dollar valuations by the early 2030s, as several promising B7-H3-targeted therapies are expected to gain regulatory approval in key markets like the U.S., Europe, and Asia-Pacific.

Several factors are driving this growth:

Rising Cancer Incidence: The global rise in cancer incidence, particularly in prostate, lung, and breast cancers, is expected to increase demand for targeted therapies like B7-H3 inhibitors.

Improved Patient Stratification: Biomarker-based approaches are improving the ability to identify patients most likely to benefit from B7-H3-targeted therapies, driving adoption of these treatments.

Combination Therapies: B7-H3 inhibitors are being evaluated in combination with other immunotherapies, such as PD-1/PD-L1 inhibitors, to enhance treatment efficacy and overcome resistance mechanisms in tumors.

Regulatory Approvals: The approval of B7-H3 inhibitors by regulatory agencies such as the U.S. FDA and European Medicines Agency (EMA) will accelerate market growth, especially as clinical trial results continue to support their safety and efficacy.

Conclusion

The B7-H3 inhibitors market is positioned for significant expansion, with promising therapies on the horizon for a variety of cancers. As the understanding of B7-H3’s role in immune evasion and tumor progression deepens, the market will see an increasing number of targeted therapies moving through clinical trials and toward regulatory approval. With a growing target population, robust competition, and increasing investment in cancer immunotherapy, the B7-H3 market size is expected to experience substantial growth, reaching new heights by 2034. The future of B7-H3-targeted therapies holds great promise for improving cancer care and outcomes for patients worldwide.

Latest Reports

Contraceptive Devices Market | Crohns Disease Cd Market | Cutaneous T-cell Lymphoma Market | Diabetic Neuropathy Market | Ehlers-danlos Syndrome Market | Encephalitis Market | Epidermolysis Bullosa Market | Familial Amyloid Polyneuropathy Market | Healthcare Competitive Benchmarking | Hepatic Encephalopathy Epidemiology Forecast | Hepatitis B Virus Market | Hepatitis D Market | Hereditary Spastic Paraplegias Market | Hpv-induced Cancers Market | Human Papillomavirus Positive Cancer Market | Hyperkalemia Market | Nontuberculous Mycobacteria Infection Market | Post-bariatric Hypoglycemia Market | Postsurgical Pain Market | Primary Progressive Multiple Sclerosis Ppms Market | Surgical Stapling Devices Market | Vascular Access Devices Market | Vascular Dementia Market | Wound Closure Devices Market | Xerostomia Market

[medlama]

Atezolizumab Injection : A Guide to Tecentriq and Its Uses in India

In recent years, immunotherapy has emerged as a groundbreaking approach in cancer treatment, offering renewed hope for patients facing difficult-to-treat cancers. One such immunotherapy drug is Atezolizumab, marketed under the brand name Tecentriq. This drug has shown promising results in treating a variety of cancers, including lung cancer, bladder cancer, and specific forms of breast cancer. However, like many innovative treatments, the cost can be a concern, particularly in India. In this post, we will explore the atezolizumab injection price, its uses, and what patients can expect when considering Tecentriq as part of their cancer treatment plan.

Atezolizumab – Uses & Introduction

Atezolizumab is a cancer immunotherapy drug classified as a PD-L1 inhibitor. It enhances the immune system’s ability to recognize and destroy cancer cells. In normal conditions, cancer cells evade the immune system by producing a protein called PD-L1, which essentially “turns off” the body’s immune response against them. Atezolizumab blocks this PD-L1 protein, allowing the immune system to detect and attack cancer cells more effectively.

Atezolizumab injection is used to treat various cancers, including:

Non-small cell lung cancer (NSCLC)

Small cell lung cancer (SCLC)

Urothelial carcinoma (bladder cancer)

Triple-negative breast cancer (TNBC)

Hepatocellular carcinoma (liver cancer)

It is often prescribed for advanced-stage cancers or when the cancer has metastasized (spread to other parts of the body). Atezolizumab is typically administered alongside chemotherapy or other cancer treatments, depending on the type and stage of the cancer.

How Does Atezolizumab Work? The Mechanism of Action

Understanding how Atezolizumab works can provide patients with a clearer perspective on its role in cancer treatment. Under normal circumstances, the immune system attacks anything recognized as harmful, including cancer cells. However, tumors can avoid immune detection by producing PD-L1, which effectively shuts down the immune response.

Atezolizumab interrupts this process by binding to PD-L1 and preventing it from interacting with the PD-1 receptor on immune cells. This restores the immune system’s ability to recognize and fight cancer cells, allowing for a more targeted and effective treatment. As a result, many patients experience improved outcomes, particularly in advanced cancers.

Tecentriq 1200mg Injection Price in India

Like most immunotherapy drugs, the cost of Atezolizumab is significant, and it’s important to consider the Tecentriq 1200mg injection price when planning treatment. In India, the price typically ranges from ₹2.5 lakh to ₹3.5 lakh per dose, depending on the healthcare provider, location, and any applicable discounts or assistance programs.

The high cost reflects the advanced nature of the drug’s formulation and the research behind its development. For many patients, Atezolizumab requires multiple doses over a period of months, depending on the cancer type and stage, which can substantially increase the total treatment cost.

Atezolizumab Injection Price: What Influences the Cost?

Several factors contribute to the atezolizumab injection price in India:

Manufacturer: Tecentriq is produced by Roche, a global pharmaceutical leader, and the cost reflects the investment in research, clinical trials, and obtaining regulatory approvals.

Healthcare Facility: The cost can vary depending on whether treatment is administered in private hospitals, public healthcare facilities, or specialized cancer clinics.

Insurance Coverage: Patients with comprehensive insurance may have some of the costs covered, though policies can differ widely, so it’s important to confirm coverage specifics.

Number of Doses: Treatment duration and the number of doses required depend on the type of cancer and its progression, directly impacting overall costs.

Although the atezolizumab injection price can be high, it offers life-extending benefits for many cancer patients, making the investment in treatment worthwhile for eligible individuals.

 Financial Assistance and Support Options

Given the high Tecentriq 1200mg injection price, financial assistance programs are available to help patients manage treatment costs. These include:

Insurance: Health insurance providers may offer partial or full coverage for immunotherapy treatments like Atezolizumab. Check with your insurance provider to confirm coverage.

Pharmaceutical Assistance Programs: Roche offers patient support programs that can reduce the out-of-pocket costs for Tecentriq. For those in need of financial aid, Medlama can assist in connecting patients with such programs to obtain the best possible price for Atezolizumab.

Government Health Schemes: Programs like Ayushman Bharat offer affordable cancer treatment for eligible patients in India, providing further financial support.

Non-Profit Organizations: Organizations like the Indian Cancer Society and CanSupport provide financial assistance to cancer patients who cannot afford treatment costs.

Exploring these options can significantly ease the financial burden of cancer treatment.

What to Expect During Atezolizumab Treatment

Atezolizumab is administered as an IV infusion, typically every two to four weeks, depending on the patient’s specific treatment plan. Each session lasts about 30 to 60 minutes.

Common side effects include fatigue, nausea, and reduced appetite. Some patients may also experience immune-related side effects, such as inflammation in organs like the lungs, liver, or intestines. Close monitoring by a healthcare team is essential to manage these side effects and ensure treatment efficacy.

Conclusion: Balancing Cost and Treatment Effectiveness

Atezolizumab, sold under the brand name Tecentriq, represents a breakthrough in cancer treatment, offering new hope for patients with advanced or difficult-to-treat cancers. However, the atezolizumab injection price in India, ranging between ₹2.5 lakh and ₹3.5 lakh per dose, can be a significant financial concern. 

For those exploring this treatment, it’s essential to explore available financial assistance programs. Consult with your healthcare provider or pharmacy counselor at Medlama to find the best possible offers and support options, ensuring you receive the treatment without an overwhelming financial burden.

Source URL- https://medlama.com/product/tecentriq/

[soumyafwr]

https://twikkers.nl/blogs/242598/Drugs-for-Non-small-Cell-Lung-Cancer-Market-Analysis-Size

Drugs for Non-small Cell Lung Cancer Market Analysis, Size, Share, and Forecast 2031